A crisis in ADHD care is unfolding in England, with waiting lists for NHS services overwhelmed by patients returning from private clinics. This situation is not only causing long delays but also risking treatment gaps for those in need.
The issue, as explained by a major NHS trust, stems from the increasing number of patients who are referred to private clinics using health service funding but then request to be transferred back to NHS care due to various challenges. These challenges include private clinics' assessments not always meeting the guidelines set by the National Institute for Health and Care Excellence, and a lack of qualified staff to support continued prescribing.
The consequences for patients are severe. Some are facing the financial burden of prescription costs exceeding £200 per month, while others are at risk of treatment disruptions due to shared care agreements being withdrawn. One father shared his son's story, highlighting the impact of medication on his ability to maintain a job and manage daily life, and the potential harm if treatment stops.
But here's where it gets controversial... The Midlands partnership university NHS foundation trust (MPFT) has acknowledged the strain on their services due to the influx of patients returning from private clinics. In a letter, they highlighted the long waiting times, reduced capacity for new cases, and the risks of delays and gaps in care.
The Guardian's previous investigation revealed that the NHS in England is overspending on ADHD services, with a significant portion of this spending going towards private assessments that lack proper regulation. As awareness of ADHD has grown, demand for assessments has skyrocketed, leading to overstretched NHS services and a waiting list of over 500,000 people.
In an attempt to manage the demand, the NHS has been paying private providers to conduct assessments and, in some cases, provide treatment through prescribing. This practice, known as the "right to choose" pathway, allows patients in England to opt for private assessment, diagnosis, and initial treatment, with the potential for a shared-care agreement with their GP for ongoing prescribing.
However, this system is far from perfect. It is often fragmented, lacking clear clinical standards. A letter from MPFT, written by Megan Cann, a customer service facilitator, based on comments from Upkar Jheeta, highlights the challenges. It was sent in response to a patient whose shared care agreement was abruptly withdrawn after years of treatment.
The letter acknowledges the distress caused by the sudden withdrawal of prescribing and raises concerns about the potential destabilization of the patient's condition. It also points out the limitations of the "right to choose" pathway, stating that while the provider was chosen by the patient, they were unable to prescribe medication, which is a common issue with private ADHD providers.
And this is the part most people miss... The local integrated care board has introduced a right to choose vetting service to address these concerns. A spokesperson for NHS Staffordshire and Stoke-on-Trent ICB has stated their commitment to ensuring patients receive the necessary care and medication, and they are reviewing the case and their processes for working with private providers.
This complex situation raises important questions about the balance between patient choice, regulation, and the provision of essential healthcare services. What are your thoughts on this issue? Do you think the current system is fair and effective, or is there a need for reform? Feel free to share your opinions and experiences in the comments below!
